The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation.

Abstract

In infants, especially with novel previously undescribed mutations of the KATP channel causing neonatal diabetes, in vitro studies can be used to both predict the response to sulphonylurea treatment and support a second trial of glibenclamide at higher than standard doses if the expected response is not observed.